Ultragenyx Recently Exercises Option to Buy 600,000 Shares of Arcturus' Common Stock

Ultragenyx Pharmaceutical Inc. announced recently that it would exercise its option to buy 600,000 shares of Arcturus Therapeutics Holdings Inc.'s common stock at $16 per share.

San Diego-based Arcturus is a messenger RNA medicines company that is working on a vaccine for COVID-19.

Ultragenyx is a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, according to the company

“The new investment from Ultragenyx is a testament to the strength of our long-term collaboration in developing nucleic acid therapies,” said Andrew Sassine, chief financial officer of Arcturus. “The additional funding will support our clinical programs, including our efforts to move our COVID-19 vaccine candidate into clinical testing this summer.”